HIV mutation literature information.


  Development of an optimized dose for coformulation of zidovudine with drugs that select for the K65R mutation using a population pharmacokinetic and enzyme kinetic simulation model.
 PMID: 18838591       2008       Antimicrobial agents and chemotherapy
1Abstract: Therefore, ZDV could be coformulated with these agents as a ""resistance
Abstract: In vitro selection studies and data from large genotype databases from clinical studies have demonstrated that tenofovir disoproxil fumarate and abacavir sulfate select for the K65R mutation in the human immunodeficiency virus type 1 polymerase region.
Abstract: Studies performed in vitro and in humans suggest that viruses containing the K65R mutation remained susceptible to zidovudine (ZDV) and other thymine nucleoside antiretroviral agents.


  Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting.
 PMID: 18855659       2008       Current HIV research
Abstract: Patients with K65R (3.4% vs 17.9%, p=0.005), Q151M (5.9% vs 20.5%, p=0.012), and multi-NRTI resistance mutations (16.8% vs 48.7%, p<0.001) when compared to patients with >2 etravirine-RAMs.


  HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy.
 PMID: 19000027       2008       AIDS research and human retroviruses
Abstract: Ninety-one percent of patients harbored resistance mutations; the most frequent NRTI mutations were M184V/I (37%), D67N (32%), T215Y/F (25%), K70R (21%), M41L (20%), K219Q/E (14%), and K65R (14%), reflecting the frequent use of lamuvidine and zidovudine.


  Silent mutations are selected in HIV-1 reverse transcriptase and affect enzymatic efficiency.
 PMID: 19005273       2008       AIDS (London, England)
Introduction: The K65R, K70E, L74V, Q151M and M184V mutations primarily increase the selectivity of RT for the incorporation of a natural dNTP substrate over a NRTI-triphosphate.
Result: Accordingly, we were also interested in the ability of RT enzymes conta
Discussion: Another unique feature of subtype C virus is that the K65R mutation which develops in subtype C is AGG, whereas in subtype B it is almost exclusively AGA (data not shown).


  Mechanism by which a glutamine to leucine substitution at residue 509 in the ribonuclease H domain of HIV-1 reverse transcriptase confers zidovudine resistance.
 PMID: 19067547       2008       Biochemistry
Result: The mutations K65R, K70E, L74V, Q151 M, and M184V increase the selectivity of RT for incorporation of the natural dNTP substrate versus the NRTI-triphosphate (NRTI-TP).


  Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence.
 PMID: 19092977       2008       AIDS reviews
Abstract: Virologic and biochemical data suggest that K65R is more likely to emerge in subtype C HIV-1.


  Broad advances in understanding HIV resistance to antiretrovirals: report on the XVII International HIV Drug Resistance Workshop.
 PMID: 19195337       2008       Antiviral therapy
Abstract: Mechanistic research explored resistance to the integrase inhibitor raltegravir, K65R-mediated resistance to tenofovir and the role of connection domain mutations in resistance to zidovudine.


  Site-directed mutagenesis in the fingers subdomain of HIV-1 reverse transcriptase reveals a specific role for the beta3-beta4 hairpin loop in dNTP selection.
 PMID: 17055529       2007       Journal of molecular biology
Abstract: The K65A mutant behaved similarly to the deletion mutant displaying dependence on Watson-Crick hydrogen bonding, increased fidelity and reduced dNTP-binding, while the K65R was more akin to wild-type enzyme.
Abstract: Two substitution mutants, K65R and K65A were studied.


  Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.
 PMID: 17088490       2007       Antimicrobial agents and chemotherapy
Abstract: NRTI-TP discrimination by the K70E (and K65R) mutation was primarily due to decreased rates of NRTI-TP incorporation and not to changes in analog binding affinity.
Abstract: By comparison, K65R RT demonstrated 12.4-, 12.0-, and 13.1-fold-higher levels of resistance, respectively, toward the same analogs.
Abstract: Taken together, these findings indicate that the K70E mutation, like the K65R mutation, reduces susceptibility to NRTI by selectively decreasing NRTI-TP incorporation and is antagonistic to TAM-mediated nucleotide excision.


  Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
 PMID: 17205457       2007       Clinical infectious diseases
Abstract: Patients with an HIV-1 RNA load of >4 log copies/mL at the time of treatment failure had higher prevalence of thymidine analogue mutations (P=.041), K65R (P=.031), and Q151M (P=.008) mutations.
Abstract: Thymidine analogue mutations, K65R, and Q151M were observed in 37%, 6%, and 8% of patients, respectively.



Browser Board

 Co-occurred Entities




   Filtrator